Patents by Inventor Charlotte A. Kensil
Charlotte A. Kensil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8808692Abstract: The present invention relates to pharmaceutical compositions that are useful for the prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response, and methods of formulating the compositions. The compositions comprise an immunoreactive reagent (i.e., an antigen binding protein comprising an antigen binding region and a region or regions of an antibody that mediate antibody dependent immunological processes) and a saponin. The present invention also relates to methods of using the compositions of the invention for the prevention and/or treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response.Type: GrantFiled: November 18, 2010Date of Patent: August 19, 2014Assignee: CSL LimitedInventor: Charlotte A. Kensil
-
Publication number: 20110064749Abstract: The present invention relates to pharmaceutical compositions that are useful for the prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response, and methods of formulating the compositions. The compositions comprise an immunoreactive reagent (i.e., an antigen binding protein comprising an antigen binding region and a region or regions of an antibody that mediate antibody dependent immunological processes) and a saponin. The present invention also relates to methods of using the compositions of the invention for the prevention and/or treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response.Type: ApplicationFiled: November 18, 2010Publication date: March 17, 2011Inventor: Charlotte A. Kensil
-
Patent number: 7858589Abstract: Vaccine compositions of immunostimulatory oligonucleotides and saponin adjuvants and antigens and the use thereof for stimulating immunity, enhancing cell-mediated immunity, and enhancing antibody production are disclosed. Also described are immune adjuvant compositions comprising immunostimulatory oligonucleotides and saponin adjuvants, as well as methods for increasing an immune response using the same.Type: GrantFiled: March 10, 2006Date of Patent: December 28, 2010Assignee: Antigenics Inc.Inventor: Charlotte A. Kensil
-
Publication number: 20060210555Abstract: The present invention relates to pharmaceutical compositions that are useful for the prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response, and methods of formulating the compositions. The compositions comprise an immunoreactive reagent (i.e., an antigen binding protein comprising an antigen binding region and a region or regions of an antibody that mediate antibody dependent immunological processes) and a saponin. The present invention also relates to methods of using the compositions of the invention for the prevention and/or treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response.Type: ApplicationFiled: December 20, 2002Publication date: September 21, 2006Applicant: Antigenics, Inc.Inventor: Charlotte Kensil
-
Publication number: 20060177458Abstract: Vaccine compositions of immunostimulatory oligonucleotides and saponin adjuvants and antigens and the use thereof for stimulating immunity, enhancing cell-mediated immunity, and enhancing antibody production are disclosed. Also described are immune adjuvant compositions comprising immunostimulatory oligonucleotides and saponin adjuvants, as well as methods for increasing an immune response using the same.Type: ApplicationFiled: March 10, 2006Publication date: August 10, 2006Inventor: Charlotte Kensil
-
Patent number: 7049302Abstract: Vaccine compositions of immunostimulatory oligonucleotides and saponin adjuvants and antigens and the use thereof for stimulating immunity, enhancing cell-mediated immunity, and enhancing antibody production are disclosed. Also described are immune adjuvant compositions comprising immunostimulatory oligonucleotides and saponin adjuvants, as well as methods for increasing an immune response using the same.Type: GrantFiled: August 6, 1999Date of Patent: May 23, 2006Assignee: Antigenics Inc.Inventor: Charlotte A. Kensil
-
Publication number: 20050191310Abstract: Certain novel compositions of the adjuvant saponin QS-21 having improved properties are disclosed. The compositions of the present invention are designed (1) to minimize the lytic effects of QS-21, (2) to improve the tolerance of QS-21 containing formulations in humans or other animals, (3) to stabilize the QS-21 from alkaline hydrolysis and/or (4) to maintain the high adjuvant potency of the QS-21 product. These compositions may be employed with vaccines comprising proteins or peptides, polysaccharides, lipids, or nucleic acids.Type: ApplicationFiled: October 3, 2003Publication date: September 1, 2005Inventors: Charlotte Kensil, Gerald Beltz
-
Patent number: 6645495Abstract: Certain novel compositions of the adjuvant saponin QS-21 having improved properties are disclosed. The compositions of the present invention are designed (1) to minimize the lytic effects of QS-21, (2) to improve the tolerance of QS-21 containing formulations in humans or other animals, (3) to stabilize the QS-21 from alkaline hydrolysis and/or (4) to maintain the high adjuvant potency of the QS-21 product. These compositions may be employed with vaccines comprising proteins or peptides, polysaccharides, lipids, or nucleic acids.Type: GrantFiled: August 28, 1998Date of Patent: November 11, 2003Assignee: Antigenics, Inc.Inventors: Charlotte A. Kensil, Gerald A. Beltz
-
Patent number: 6524584Abstract: The present invention is in the field of medicinal chemistry. In particular, the invention is related to vaccines comprising novel combinations of saponin adjuvants, to pharmaceutical compositions and vaccines comprising these novel combinations, to methods of using these novel combinations to enhance the immune response of an individual to an antigen, and to the use of the novel combinations to increase the immunogenicity of vaccines.Type: GrantFiled: May 14, 2001Date of Patent: February 25, 2003Assignee: Antigenics, Inc.Inventor: Charlotte A. Kensil
-
Publication number: 20020044940Abstract: The present invention is in the field of medicinal chemistry. In particular, the invention is related to vaccines comprising novel combinations of saponin adjuvants, to pharmaceutical compositions and vaccines comprising these novel combinations, to methods of using these novel combinations to enhance the immune response of an individual to an antigen, and to the use of the novel combinations to increase the immunogenicity of vaccines.Type: ApplicationFiled: May 14, 2001Publication date: April 18, 2002Inventor: Charlotte A. Kensil
-
Publication number: 20020044951Abstract: Nonpeptide antigens were isolated and purified from Mycobacterium tuberculosis. The antigens were used in vaccine compositions, pharmaceutical compositions and methods to elicit an immune response to Mycobacterium tuberculosis in a mammal.Type: ApplicationFiled: April 4, 2001Publication date: April 18, 2002Inventors: Gui Liu, Gerald Beltz, Kenneth LeClair, Daniel Cox, Charlotte Kensil
-
Publication number: 20010034330Abstract: Compositions comprising oligonucleotides comprising at least one unmethylated CpG dinucleotide and saponin and the use thereof for stimulating innate immunity and enhancing natural killer cell activity are disclosed.Type: ApplicationFiled: January 12, 2001Publication date: October 25, 2001Inventor: Charlotte Kensil
-
Patent number: 6231859Abstract: The present invention is in the field of medicinal chemistry. In particular, the invention is related to vaccines comprising novel combinations of saponin adjuvants, to pharmaceutical compositions and vaccines comprising these novel combinations, to methods of using these novel combinations to enhance the immune response of an individual to an antigen, and to the use of the novel combinations to increase the immunogenicity of vaccines.Type: GrantFiled: December 2, 1997Date of Patent: May 15, 2001Assignee: Aquila Biopharmaceuticals, Inc.Inventor: Charlotte A. Kensil
-
Patent number: 5650398Abstract: Disclosed herein are modified saponins or fractions thereof obtainable by modification of a crude Quillaja saponaria extract or by modification of purified saponins obtainable from a crude Quillaja saponaria extract useful in pharmaceutical compositions for enhancing the transport of pharmacologically active substances across mucous membranes of an animal. Also disclosed are modified saponins having reduced irritability wherein the aldehyde group is reduced and the fatty acid moiety may be removed by hydrolysis. Also disclosed are pharmaceutical compositions comprising the modified saponins of the invention.Type: GrantFiled: June 2, 1995Date of Patent: July 22, 1997Assignee: Cambridge Biotech CorporationInventors: Charlotte A. Kensil, Sean Soltysik, Dante J. Marciani, Joanne Recchia
-
Patent number: 5583112Abstract: Saponin/antigen conjugates and the use thereof for enhancing immune responses in individuals are disclosed. The saponins may be substantially pure or mixtures of saponins.Type: GrantFiled: July 2, 1992Date of Patent: December 10, 1996Assignee: Cambridge Biotech CorporationInventors: Charlotte A. Kensil, Sean Soltysik, Dante J. Marciani
-
Patent number: 5443829Abstract: Disclosed herein are modified saponins or fractions thereof obtainable by modification of a crude Quillaja saponaria extract or by modification of purified saponins obtainable from a crude Quillaja saponaria extract useful in pharmaceutical compositions for enhancing the transport of pharmacologically active substances across mucous membranes of an animal. Also disclosed are modified saponins having reduced irritability wherein the aldehyde group is reduced and the fatty acid moiety may be removed by hydrolysis. Also disclosed are pharmaceutical compositions comprising the modified saponins of the invention.Type: GrantFiled: September 24, 1993Date of Patent: August 22, 1995Assignee: Cambridge Biotech CorporationInventors: Charlotte A. Kensil, Sean Soltysik, Dante J. Marciani
-
Patent number: 5352449Abstract: The invention relates to antigenic preparations useful for inducing the production of antibodies in a cat which will bind to epitopes on feline leukemia virus. Also disclosed are immunogenic compositions and methods for immunizing a cat to enable the production of antibodies to feline leukemia virus.Type: GrantFiled: April 14, 1992Date of Patent: October 4, 1994Assignee: Cambridge Biotech CorporationInventors: Gerald A. Beltz, Dante J. Marciani, Chung-Ho Hung, Charlotte A. Kensil
-
Patent number: 5273965Abstract: Methods for enhancing the transport of pharmacologically active substances across mucous membranes of an animal by administration of pharmaceutical compositions comprising modified saponins or fractions thereof obtainable by modification of a crude Quillaja saponaria extract or by modification of purified saponins obtainable from a crude Quillaja saponaria extract. Also disclosed are modified saponins having reduced irritability wherein the fatty acid moiety is removed by hydrolysis or the aldehyde group is reduced. Also disclosed are pharmaceutical compositions comprising the modified saponins of the invention.Type: GrantFiled: July 2, 1992Date of Patent: December 28, 1993Assignee: Cambridge Biotech CorporationInventors: Charlotte A. Kensil, Sean Soltysik, Dante J. Marciani
-
Patent number: 5057540Abstract: Substantially pure saponins are disclosed. The saponins of the present invention are useful as immune adjuvants. Disclosed as well are immune response-provoking compositions comprising an antigen in admixture with the substantially pure saponins.Type: GrantFiled: August 27, 1990Date of Patent: October 15, 1991Assignee: Cambridge Biotech CorporationInventors: Charlotte A. Kensil, Dante J. Marciani